The short version of FSFI endpoint fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-13. Anything still debated is marked as such rather than presented as settled.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
=== Policy and regulatory environment === In order for digital agriculture to spread, national governments, multilateral organizations, and other policymakers must provide a clear regulatory framework so that stakeholders feel confident investing in digital agriculture solutions. Policy designed for the pre-Internet era prevents the advancement of "smart agriculture," as does regulatory ambiguity. Furthermore, a blurry line between personal and business data when discussing family farms complicates data regulation. The unanswered regulatory questions mostly concern big data, and they include:
=== Ubiquitin-independent degradation === Although most substrates must be ubiquitinated before being degraded by the 26S proteasome, there are some exceptions to this general rule, especially when the proteasome plays a normal role in the post-translational processing of the protein. The proteasomal activation of NF-κB by processing p105 into p50 via internal proteolysis is one major example. Some proteins that are hypothesized to be unstable due to intrinsically unstructured regions, are degraded in a ubiquitin-independent manner. Ubiquitin-independent mechanisms targeting key cell cycle regulators such as p53 have also been reported, although p53 is also subject to ubiquitin-dependent degradation. Finally, structurally abnormal, misfolded, or highly oxidized proteins are also subject to ubiquitin-independent and 19S-independent degradation under conditions of cellular stress. The most well-known example of a ubiquitin-independent proteasome substrate is the enzyme ornithine decarboxylase (ODC). ODC is degraded upon the expression and binding to a cofactor, Ornithine decarboxylase antizyme (AZ) that breaks the ODC dimer. ODC contains either a C-terminal disordered region (in human) or an N-terminal disordered region (in yeast) is necessary for degradation and is proposed to engage the AAA motor of the 19S RP, however the mechanistic details of this interaction have yet to be identified. Another example of ubiquitin independent degradation is Thymidine synthetase, where an N-terminal disordered region is essential for degradation.
Faraday constant (F) A unit of electric charge widely used in electrochemistry equal to the negative of the molar charge (electric charge per mole) of electrons. It is equal to approximately 96,500 coulombs per mole (F = 96485.33212... C/mol).
== Structure == This group of cysteine peptidases belong to MEROPS peptidase family C60 (clan C-) and include the members of several subfamilies of sortases. Another sub-family of sortases (C60B in MEROPS) contains bacterial sortase B proteins that are approximately 200 residues long. The protein cleaving and ligating function of the sortase enzyme is reliant on the structure of the enzyme binding site and the presence of the correct binding site on the target protein. The requirement of a binding motif limits the versatility of the sortase enzyme and requires the addition of a short protein tag in cases when the desired protein doesn't contain the necessary binding site.
== Further implications == In 1979, the practice was abolished in California. It is estimated that approximately 20,000 women were sterilized in total. The 2021–22 state budget package included funding $7.5 million for the California Forced or Involuntary Sterilization Compensation Program legislation, to begin Jan. 1, 2022, administered by the California Victim Compensation Board (CalVCB), for survivors of state-sponsored sterilization 1909 through 1979 and survivors of involuntary sterilizations in women's prisons after 1979 to ask about and apply for compensation (www.victims.ca.gov/fiscp or reach out to CalVCB at 800-777-9229 or fiscp@victims.ca.gov). Researchers estimated hundreds of Californians are alive who might hypothetically qualify before the December 2023 deadline, but reportedly as of early September 2023, only 101 applications had been approved, with seven cases closed as incomplete, and 339 denied.
Sources: en.wikipedia.org
=== Protein complex immunoprecipitation (Co-IP) === Immunoprecipitation of intact protein complexes (i.e. antigen along with any proteins or ligands that are bound to it) is known as co-immunoprecipitation (Co-IP). Co-IP works by selecting an antibody that targets a known protein that is believed to be a member of a larger complex of proteins. By targeting this known member with an antibody it may become possible to pull the entire protein complex out of solution and thereby identify unknown members of the complex. This works when the proteins involved in the complex bind to each other tightly, making it possible to pull multiple members of the complex out of the solution by latching onto one member with an antibody. This concept of pulling protein complexes out of solution is sometimes referred to as a "pull-down". Co-IP is a powerful technique that is used regularly by molecular biologists to analyze protein–protein interactions.
The researchers have mentioned that part of the liquid-disorder formation occurs possibly be interrupting the hydrophobic region of the phospholipids, by binding closely towards the hydrophilic region of the phospholipid, and acting as "filler" since ethanol cannot closely align with the neighboring phospholipids. All of these possible mechanisms can be contributed to ethanol's amphiphilic nature.
Regarded as a founder of CJNG, Don Rodo was vital to the cartel's money laundering and property purchasing operations, reportedly also working alongside CJNG notary public offices in Ciudad Guzmán and Autlán de Navarro to manage changes of ownership of the properties he purchased for El Mencho. In February 2026, it was reported that Abraham was still "in the hands of Mexican authorities" since his February 2025 arrest. On 27 April 2026 Mexican special forces arrested Audias Flores Silva, who is considered a potential successor to "El Mencho", leading the El Jalisco cartel. The Mexican Navy confirmed that the operation to arrest Silva resulted from 19 months of surveillance and also involved more than 500 personnel, six helicopters, and intelligence and reconnaissance aircraft. According to Mexican Secretary of the Navy the operation had in fact started in October 2024 “when the Mexican Navy activated intelligence efforts focused on a priority target (Flores Silva) linked to one of the country’s main criminal organizations (the CJNG). From that moment on, a discreet and sustained systematic follow-up was carried out, based on field intelligence, intelligence gathering, and international cooperation.”
CH3COOH → CH4 + CO2 In laboratories, clumped isotope compositions of methane generated by hydrogenotrophic methanogens, acetoclastic methanogens (biodegradation of acetate), and methylotrophic methanogens are universally out of equilibria. It has been proposed that the reversibility of methanogenic enzyme is key to the kinetic isotope effect expressed in biogenic methane.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.